Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATXN2 | Q99700 | 4/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21323309 | 0.90 | GPR183 (0.39) | ATXN2ENPP2DGAT2GPR183HDAC1 | |
| SCHEMBL16963465 | 0.90 | GPR183 (0.39) | ATXN2ENPP2DGAT2GPR183HDAC1 | |
| SCHEMBL16963089 | 0.90 | GPR183 (0.39) | ATXN2ENPP2DGAT2GPR183HDAC1 | |
| SCHEMBL21313899 | 0.79 | GPR183 (0.34) | ATXN2ENPP2GPR183HPGD | |
| SCHEMBL16963466 | 0.79 | GPR183 (0.34) | ATXN2ENPP2GPR183HPGD | |
| SCHEMBL21323334 | 0.79 | GPR183 (0.49) | ATXN2ENPP2DGAT2GPR183HDAC1 | |
| SCHEMBL16963560 | 0.79 | GPR183 (0.49) | ATXN2ENPP2DGAT2GPR183HDAC1 | |
| SCHEMBL16963565 | 0.79 | GPR183 (0.49) | ATXN2ENPP2DGAT2GPR183HDAC1 | |
| SCHEMBL16962945 | 0.78 | ENPP2 (0.46) | ATXN2ENPP2GPR183 | |
| SCHEMBL16962947 | 0.78 | ENPP2 (0.46) | ATXN2ENPP2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | ATXN2 791/4885ENPP2 1981/4885DGAT2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.